



MINUTES

MEETING OF THE BORDERS FORMULARY COMMITTEE TO BE HELD
ON WEDNESDAY, 9 APRIL 2014 @ 12.30 P.M. IN THE
ESTATES MEETING ROOM - BGH

1. Present: Alison Wilson (Chair), Liz Leitch, Adrian Mackenzie, Hamish McRitchie
Apologies: Ros Anderson, Elliot Longworth, Paul Marynicz, Craig Wheelans; Catherine Scott

Observing Fiona Bennie, Substance Misuse Liaison Nurse; Andrew Strange (Trainee GP), Dr Neary in attendance for item 6 - Apixaban

Item No.	Situation	Background	Assessment	Recommendation	Person Responsible	Timescale
2.	Declaration of Interest: Adrian Mackenzie received payment for attending an advisory meeting in relation to dimethyl fumarate					
3.	Minute of BFC meeting of 12 February 2014	Minute from last BFC meeting.	Read and noted for accuracy.	Mirabegron – Liz to get back to Mr Alhasso – amend minute	LS	Complete
4.	Matters Arising From Previous Minute:					
	Thiotepa Eye Drops	Risk assessment of preparing product in our aseptic unit.	Advice required of continued use. VS unaware of action as not attendee to this meeting. LL Update: Prescriber keen to continue use of Thiotepa. LL searched information on Thiotepa prevention of pterygium. LL contacted Eye	LL to speak to Dr Murray.	VS/SH LL	14.05.14

			Pavillion – Advice now sought from Committee:			
	Acetylcysteine	Indication for use is patient preparation for upper GI endoscopy.	<p>Drug will remove gastric mucus and bubbles improving the endoscopic view and giving a better chance of detecting early gastric cancer.</p> <p>LL has email trail from Dr Fletcher – GI Team. Dr Fletcher keen to support its use.</p>	Approve for 50 patients – provide feedback	LL	09.04.14
	Formulary App	MRG approved fund for Formulary App.	<p>Preferred Supplier Nugensis H McR – required to check either App or content copyright before going into public domain.</p> <p>Formulary contains dose information – what process does Committee wish Liz to undertake before it goes for formatting.</p> <p>Committee happy with robust formulary process.</p>	<p>Liz will check with IT</p> <p>LL email individuals regarding their individual chapters.</p>	LL/AW LL	14.05.14
5.	Non Formulary Request Form	Draft Non Formulary Request Form	<p>Approval Required</p> <p>LL email correspondence re prescribing non formulary</p>	Support as a test of change. When notify people of new formulary app	LL/AW	14.05.14

			products. Query use this form in this context e.g. Locum Consultants/Non SMC approved?	– send out form for non formulary requests		
	BJF 3 Respiratory	The choice of inhaler is made from NHS Borders joint formulary on the basis of the most effective delivery device, which can be used by each individual respiratory patient.	For discussion/Approval Required	Approval on proviso feedback from Dr Paul Marynicz and Dr Elliot Longworth and Craig Wheelans for comments. Liz will email document for feedback	LL/AW	09.04.14
	New Oral Anticoagulant March 2014	New Oral Anticoagulant - Amendment	For discussion/Approval Confusion regarding where NHS stood on new anticoagulants. LL met with Formulary Group – feedback from Craig – in red National Guidance – Advice from SIGN – patient choice.	Approved	LL	09.04.14
6.	New Medicine Applications:					
	Apixaban	Anticoagulation 5mg twice daily	Patient has been on Warfarin for approx 7 or 8 years but compliance with medication and blood tests has been unreliable. GP feels increasingly unsafe to prescribe Warfarin. Patient LV non compaction. High risk of blood clots in left ventricle. Never be	Dr Neary in attendance. Approved in principle – subject to approval from Dr Paul Marynicz and Craig Wheelans. Let Dr Neary know	LL LL/AW	09.04.14 09.04.14

			a clinical trial as rare condition. Cant absolutely assume that drug is as good or better than Warfarin. Patient aware of situation ie off license.			
	Nicotine Mouth Spray (QuickMist)	Indication for use: it relieves and/or prevents craving and nicotine withdrawal symptoms associated with tobacco dependence. It is indicated to aid smokers wishing to quit	The oromucosal delivery system will offer quicker relief of cravings than other oral products while potentially offering a more acceptable delivery system than the nasal spray which is also quick acting.	Approved - send letter approved monitor usage and feedback in 6 months time	BFC Group	09.04.14
	Dimethyl fumarate 120mg, 240mg	Treatment of adult patients with relapsing remitting multiple sclerosis	SMC approved	Approved	BFC Group	09.04.14
	Denosumab	Application – from one male patient - Osteoporotic fractures, needs bone protecting medication, High fracture Risk		For Noting Go back ask Karen why patient cant have Zoledronic Acid?	BFC Group	09.04.14
	Single-Incision Mini-Slings	Adjustable Anchored Single-Incision Mini-Slings Versus Standard Tension-Free Mid-Urethral Slings in the Surgical Management Of Female Stress Urinary Incontinence	Trial of 2 drugs	To note/approve	LL	09.04.14

6. SCOTTISH MEDICINE CONSORTIUM RECOMMENDATIONS:			
SMC ACCEPTED MEDICINE			
<i>Recommended for use within NHS Scotland – Embargoed 7 April 2014</i>			
	Indication	Formulary Decision & Rationale for non-inclusion	Date

951/14 rilpivirine 25mg, emtricitabine 200mg, tenofovir disoproxil (as fumarate)_245mg tablet	treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load $\leq 100,000$ HIV -1 RNA copies/mL. As with other antiretroviral medicinal products, genotypic resistance testing and/or historical resistance data should guide the use of Eviplera		09.04.14
886/13 dimethyl fumarate 120mg, 240mg gastro- resistant hard capsules	Treatment of adult patients with relapsing remitting multiple sclerosis.		
Recommended for use within NHS Scotland – Embargoed 8 April 2014			
950/14 azithromycin 500mg powder for solution for infusion	the treatment of community acquired pneumonia (CAP) and pelvic inflammatory disease (PID) due to susceptible organisms in adult patients where initial intravenous therapy is required.		
Recommended for use within NHS Scotland – Embargoed 8 April 2014			
908/13 lipegfilgrastim, 6mg, solution for injection	Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).		
Recommended for use within NHS Scotland – Embargoed 7 April 2014			
920/13 afatinib 20mg, 30mg, 40mg, 50mg film-coated tablets	As monotherapy, for the treatment of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).		
SMC RECOMMENDED MEDICINES FOR RESTRICTED USE			
Recommended for Restricted use within NHS Scotland – Embargoed 7 April 2014			
944/14 ustekinumab 45mg solution for injection in pre- filled syringe	Alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug therapy has been inadequate.		
952/14 Macitentan, 10mg film coated tablets	Treatment as a monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension in adult patients of World Health Organisation Functional Class II to III		
954/14 aflibercept, 40mg/mL solution for	For adults for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion		
92/22 fluticasone	Symptomatic treatment of adults with chronic obstructive pulmonary disease		

furoate/vilanterol micrograms inhalation powder	(COPD) with a forced expiratory volume in 1 second (FEV ₁) <70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy		
441/08 lenalidomide, 7.5mg, 10mg, 15mg and 25mg hard capsules	In combination with dexamethasone, for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. (This resubmission relates to patients who have received only one prior therapy).		
Recommended for Restricted use within NHS Scotland – Embargoed 7 April 2014			
682/11 Adapalene 0.1%/benzoyl peroxide 2.5% gel	cutaneous treatment of acne vulgaris when comedones, papules and pustules are present.		
Recommended for Restricted use within NHS Scotland – Embargoed 7 April 2014			
940/14 teriflunomide, 14mg, film-coated tablets	treatment of adults with relapsing remitting multiple sclerosis (MS		
	-		
SMC MEDICINES NOT RECOMMENDED			

7.	Patient Access Schemes					
	Adapalene	Cutaneous treatment of acne vulgaris when comedones, papules and pustules are present	PASG has agreed that the PAS for Adapalene 0.1% is acceptable for implementation in NHS Scotland	To note	BFC	09.04.14
	Macitentan	long term treatment of pulmonary arterial hypertension in adult patients of World Health Organisation Functional Class 11 to 111	PASG has agreed that the PAS for Macitentan is acceptable for implementation in NHS Scotland	To Note	BFC	09.04.14
	Dimethyl Fumarate	Adult Patients with Relapsing remitting Multiple Sclerosis	PASG has agreed that the PAS for Dimethyl Fumarate 120mg and 240mg capsules is acceptable for implementation in NHS Scotland	To Note	BFC	09.04.14
	Teriflunomide	Treatment of adult patients with relapsing remitting Multiple Sclerosis	PASG has agreed that the PAS for Teriflunomide is acceptable for implementation in NHS	To Note	BFC	09.04.14

			Scotland			
	Afibercept	In combination with irnotecan/5 flurorouracil/folinic acide chemotherapy in adults with metastatis colorectal cancer that is resistant to or has progressed after an oxaliplatin containing regimen	PASG has agreed that the PAS for Afibercept is acceptable for implementation in NHS Scotland	To Note	BFC	09.04.14
	Afatinib	As monotherapy for the treatment of Epidermal Growth FactorReceptor (EGFR) TKI naïve adult patients with locally advanced or metastatis non small cell lung cancer with activating	PASG has agreed that the PAS for Afatinib is acceptable for implementation in NHS Scotland	To Note	BFC	09.04.14
7.	Immunoglobulin Request Form	This is a national document for requesting immunoglobulins	It may be useful to use in NHS Borders	For discussion by ADTC group May meeting	ADTC	09.04.14
9.	Updated Medicines Information Section on NHS inform http://www.nhsinform.co.uk/health-library/articles/m/medicinesinfo/introduction.		For agreement	For discussion then proposal at ADTC May meeting.	ADTC	09.04.14
10.	For Noting:					
	SIGN Guidelines	SIGN 137 Management of Lung Cancer	This guideline replaces SIGN 80. It covers all aspects of the management of patients with small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), and reflects the most recent evidence on diagnostic and staging investigations, surgery, radiotherapy and systemic anti-cancer therapy.		BFC Group	09.04.14
	BFC Annual Report	Annual Report for 2013/14	Elliot Longworth not official	LS take off Report	BFC Group	Complete

	2013/14		member of the Committee			
	Copies of Borders Joint Formulary	Copies of the Borders Joint Formulary to external persons no longer charged for.	A decision has been made to no longer charge people for copies of the BFC.	Will be available for downloading.	BFC Group	Complete
	A.O.C.B.					
	Date of Next meeting: 11 th June 2014 at 12.30 p.m. in the Estates Meeting Room					